March 20th 2024
Aprocitentan is the first antihypertensive drug approved in more than 30 years that achieves its effect through a unique therapeutic pathway.
Michael A. Weber, MD, on aprocitentan approval: A new approach to managing hypertension
March 21st 2024Michael A. Weber, MD, an investigator in the PRECISION study, discusses the newly FDA approved drug aprocitentan (Tryvio), and its promise for helping patients with treatment-resistant hypertension.
Impact of Effective BP Control in Reducing CV Risk in Patients with Obesity & HTN
November 20th 2023Patients with obesity and hypertension need to be aggressively treated in order to decrease their risk of cardiovascular complications, says Dr Jonathan Parker, President of the Alabama Obesity Society.